Center for Breakthrough Medicines Launches Precision Plasmids™ Manufacturing to Accelerate Advanced Therapies into the Clinic

Superior quality Precision Plasmids™ expedite clinical trial timelines with no wait time to start manufacturing custom plasmids

Excerpt from the Press Release:

KING OF PRUSSIA, Pa., Feb. 2, 2023 /PRNewswire/ — The Center for Breakthrough Medicines (CBM), a contract development, and manufacturing organization (CDMO), has launched its plasmid manufacturing offering, Precision Plasmids™ to provide phase-appropriate plasmid on-demand for any company seeking to accelerate their path to clinic for cell and gene therapies. CBM offers NO WAIT TIMES for Precision Plasmids™ R&D grade for pre- and early clinical phases, and Precision Plasmids™ Pro grade for toxicology studies, Ph1-2 vector production, or as a starting material for mRNA. Both Precision Plasmids™ R&D and Pro are available now, while Precision Plasmids™ GMP grade will be available in April 2023.

CBM Precision Plasmids™ are of the highest quality, confirmed by Next Generation Sequencing (NGS) to guarantee the reproducibility of vector-based therapies that are manufactured using plasmids. Whether standalone starting material or within CBM’s integrated Genesis Vector Manufacturing Solution™, cell and gene therapy companies can start development and manufacturing today. Underpinned by cell banking, manufacturing, and testing at a single site, clients can expect turnaround times (TATs) of 12 weeks from a GMP master cell bank or 17+ weeks from a starting R&D plasmid.

Click the button below to read the entire Press Release:

Continue Reading The Press Release